Search results for "COLOR"

showing 10 items of 2721 documents

"Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxa…

2010

BACKGROUND: No differences in response rate (RR), progression-free survival (PFS), overall survival (OS) and quality of life (QoL) were seen in patients randomly treated with biweekly oxaliplatin plus either fluorouracil/folinic acid or capecitabine. METHODS: We investigated the independent effect of baseline clinical characteristics and physical functioning (PF) domain on RR, PFS, and OS in 310 patients who completed the EORTC QLQ-C30 questionnaire. Multivariate analyses stratified by treatment were performed. An exploratory analysis was done by grouping patients with a PF score superior or equal to the highest quartile (n = 111), included between the highest and the lowest quartiles (n = …

AdultMalemedicine.medical_specialtyMultivariate analysisColorectal cancerSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalCapecitabineTreatment Outcome; Prognosis; Aged 80 and over; Male; Retrospective Studies; Randomized Controlled Trials as Topic; Middle Aged; Kaplan-Meier Estimate; Colorectal Neoplasms; Female; Disease-Free Survival; Humans; Quality of Life; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials Phase III as Topic; Aged; Adult; Health Status Indicators; Multicenter Studies as TopicFolinic acidQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineOverall survivalHealth Status IndicatorsHumansMulticenter Studies as TopicClinical TrialsRadiology Nuclear Medicine and imagingneoplasmsmetastatic colorectal canceroxaliplatin physical functioning statusAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overbusiness.industryHematologyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryOxaliplatinPhase III as TopicTreatment OutcomeClinical Trials Phase III as TopicOncologyQuartileQuality of LifeFemaleColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospina…

2015

The etiology of multiple sclerosis (MS) is still largely unknown and it has been proposed that an impaired venous drainage from the central nervous system, defined as chronic cerebrospinal venous insufficiency (CCSVI), may play a role in this. We investigated the prevalence of extracranial venous drainage pattern alterations in a cohort of MS patients based on the 2011 revised diagnostic criteria for CCSVI. Thirty-nine MS patients and 18 healthy subjects underwent blinded extra-cranial venous echo-color Doppler sonography to reveal the presence of CCSVI. There was no statistically significant difference between MS patients and healthy controls regarding CCSVI prevalence (p value = 0.53). Th…

AdultMalemedicine.medical_specialtyNeurologyChronic cerebrospinal venous insufficiencyUltrasonography Doppler TranscranialTranscranial030204 cardiovascular system & hematologyPathogenesisMultiple sclerosis03 medical and health sciences0302 clinical medicineEcho-color Doppler sonographyInternal medicineCerebral venous outflow; Chronic cerebrospinal venous insufficiency; Echo-color Doppler sonography; Multiple sclerosis; Neurology (clinical); NeurologymedicinePrevalenceHumansUltrasonographybusiness.industryMultiple sclerosisDopplerVenous drainageMiddle Agedmedicine.diseaseSurgerySettore MED/26 - NEUROLOGIADoppler sonographyChronic cerebrospinal venous insufficiencyVenous InsufficiencyNeurologyCase-Control StudiesCohortEtiologyCardiologyFemaleNeurology (clinical)Cerebral venous outflowbusiness030217 neurology & neurosurgery
researchProduct

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter R…

2020

BACKGROUND Perioperative chemotherapy has proven valuable in several tumors, but not in colon cancer (CC). OBJECTIVE The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC. METHODS This is a French multicenter randomized phase II trial in patients with resectable high-risk T3, T4, and/or N2 CC on baseline computed tomography (CT) scan. Patients were randomized to receive either 6 months of adjuvant FOLFOX after colectomy (control) or perioperative FOLFOX for 4 cycles before surgery and 8 cycles after (FOLFOX peri-op). In RAS wild-type patients, a third arm testing perioperative FOLFOX-cetuximab was added…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinCetuximab03 medical and health sciences0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsMedicineHumanseducationColectomyColectomyAgedNeoplasm StagingTumor Regression Gradeeducation.field_of_studybusiness.industryPerioperativeMiddle Agedmedicine.diseaseInterim analysisdigestive system diseasesNeoadjuvant Therapy3. Good healthSurgeryTolerability030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologySurgeryFemaleFluorouracilFrancebusinessTomography X-Ray Computedmedicine.drugAnnals of surgery
researchProduct

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

2005

Purpose: To verify the experience of the GOIM in the treatment of advanced colorectal cancer patients with the FOLFIRI combination therapy. Patients and methods: Patients entered in three consecutive trials of the GOIM (protocols no. 9706, 9901, and 2301) were reported in this analysis. A total of 287 chemotherapy-naive patients were treated with FOLFIRI regimen: Irinotecan 180mg/m 2 on day 1 with LV5FU2 regimen (LV at 100mg/m 2 administered as a 2-hour infusion before FU at 400mg/m 2 as an intravenous bolus injection, and FU at 600mg/m 2 as a 22-hour infusion immediately after 5FU bolus injection on day 1 and 2); the treatment was repeated every 2 weeks. Results: 287 patients entered in th…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsCombination therapyColorectal cancerLeucovorinGastroenterologyFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsFOLFIRI RegimenHumansMedicineAgedSulfonamidesbusiness.industryCarcinomaLiver NeoplasmsHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanRegimenTreatment OutcomeOncologyCelecoxibFluorouracilFOLFIRIPyrazolesCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

2006

Background The aim of the study was to verify the efficacy and safety of the addition of celecoxib to FOLFIRI combination therapy in patients affected by advanced colorectal cancer. Patients and methods Eighty-one chemotherapy-naive patients entered in this randomized phase II trial of the GOIM (protocol no. 2301). Patients were randomized to receive FOLFIRI regimen (arm A): irinotecan 180 mg/m2 on day 1 with LV5FU2 regimen (LV at 100 mg/m2 administered as a 2-h infusion before FU at 400 mg/m2 as an intravenous bolus injection, and FU at 600 mg/m2 as a 22-h infusion immediately after 5-FU bolus injection on day 1 and 2); or FOLFIRI plus celecoxib 400 mg twice daily for 14 days (arm B). Both…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsLeucovorinPhases of clinical researchIrinotecanGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsFOLFIRI RegimenHumansMedicineAgedSulfonamidesbusiness.industryHematologyMiddle AgedSurgeryOxaliplatinIrinotecanRegimenTreatment OutcomeOncologyCelecoxibFluorouracilCelecoxibFOLFIRIPyrazolesCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma

2000

The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center. Tumor progression had occurred for the majority of patients during two regimens (n = 11) otherwise during one (n = 1) regimen of prior 5-FU-based chemotherapy, which had been applied in a standardized sequential fashion. As third-line therapy oxaliplatin was infused intravenously over 2 h at a dose of 60 mg/m2 prior to a 2-h infusion of FA (500 mg/m2). 5-FU (2,600 mg/m2) was subsequently given over 24 h. A favorable response was observed in 9/12 (75%) of the heavily pret…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsNauseaColorectal cancermedicine.medical_treatmentLeucovorinGastroenterologyDisease-Free SurvivalDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineInfusions IntravenousAgedNeoplasm StagingRetrospective StudiesSalvage TherapyChemotherapyDose-Response Relationship Drugbusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinRegimenFluorouracilColon neoplasmFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study

2016

Background and Aims: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. The role of immunomodulators vs clinical characteristics of IBD as risk factors for cancer was also investigated. Materials and Methods: From January 2012 to December 2014, each IBD patient with incident cancer was matched with two IBD patients without cancer for: IBD type, gender, and age. Risk factors were assessed by multivariate regression analysis. Results: IBD patients considered numbered 44619: 21953 Crohn’s disease \[CD], 22666 ulcerative colitis [UC]. Cancer occurred in 174 patients…

AdultMalemedicine.medical_specialtyPancolitisAdolescentColorectal cancerphenotypeSettore MED/12 - GASTROENTEROLOGIAcancer riskInflammatory bowel disease; cancer risk; phenotype; Adolescent; Adult; Aged; Aged 80 and over; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunologic Factors; Incidence; Inflammatory Bowel Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; Prospective Studies; Risk Factors; Young Adult; PhenotypeGastroenterologyInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicineNeoplasms80 and overmedicineHumansImmunologic FactorsProspective StudiesRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryIncidenceSettore MED/09 - MEDICINA INTERNAGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisLogistic Models030220 oncology & carcinogenesisCase-Control StudiesNested case-control studyMultivariate Analysis030211 gastroenterology & hepatologyFemalemedicine.symptombusinessInflammatory bowel disease; cancer risk; phenotypeFollow-Up Studies
researchProduct

Case report: acute portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent adult

2017

Cytomegalovirus (CMV) infection is usually asymptomatic and self-limiting in healthy individuals, but significant complications can develop in immunosuppressed patients. Venous or arterial thromboembolic phenomena are uncommon yet very serious complications of CMV infection. Most published reports describe immunosuppressed patients, but thrombotic events in CMV-infected immunocompetent individuals may also occur. We describe the case of an immunocompetent young man with acute CMV hepatitis that was complicated with portal vein thrombosis (PVT). We also review the literature regarding the association between PVT and CMV in immunocompetent patients. Thromboembolism is an underestimated but si…

AdultMalemedicine.medical_specialtyPediatricsRadiology Nuclear Medicine and ImagingSettore MED/09 - Medicina InternaCmv hepatitisUsually asymptomaticCongenital cytomegalovirus infectionCase Report030204 cardiovascular system & hematologyHepatic veinPathogenesisDiagnosis Differential03 medical and health sciences0302 clinical medicineUltrasoundmedicineInternal MedicineHumansUltrasonography Doppler ColorPortal vein thrombosiVenous Thrombosisbusiness.industryPortal VeinDopplervirus diseasesCytomegaloviruGeneral Medicinemedicine.diseaseSurgeryPortal vein thrombosisCytomegalovirus infectionHealthy individualsCytomegalovirus Infections030211 gastroenterology & hepatologyImmunocompetentComplicationbusinessImmunocompetence
researchProduct

Bacteremia after proctoscopy and hemorrhoidal injection sclerotherapy

1981

The incidence of bacteremia following proctoscopy and hemorrhoidal injection sclerotherapy was studied in 50 outpatients undergoing both procedures. Bacteremia was found in 2 per cent of the subjects after proctoscopy and in 8 per cent after sclerotherapy. None of the subjects developed symptoms of septicemia following the procedure. It is concluded that antibiotic prophylaxis should be used before sclerotherapy in patients with valvular heart disease or compromised host defense.

AdultMalemedicine.medical_specialtyPremedicationmedicine.medical_treatmentHemorrhoidsProctoscopySepsisHemorrhoidsSepsismedicineSclerotherapyHumansAgedmedicine.diagnostic_testbusiness.industryvalvular heart diseaseGastroenterologyGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseSclerosing SolutionsColorectal surgeryAnti-Bacterial AgentsProctoscopySurgeryBacteremiaAnesthesiaFemalePremedicationbusinessDiseases of the Colon & Rectum
researchProduct

Randomized clinical trial to evaluate the effects of perioperative supplemental oxygen administration on the colorectal anastomosis

2006

Abstract Background Perioperative supplemental oxygen therapy may have beneficial effects on wound healing following colorectal surgery. The aim of this study was to evaluate the effects of such therapy on colorectal anastomotic pH and partial pressure of carbon dioxide (Pco2) gap. Methods Forty-five patients undergoing anterior resection for rectal or sigmoid cancer were randomized to receive 30 or 80 per cent perioperative oxygen. Administration was commenced after induction of anaesthesia and maintained for 6 h after surgery. Intragastric and anastomotic tonometric catheters were placed in each patient and intramucosal pH (pHi) was measured immediately after operation, and 6 and 24 h lat…

AdultMalemedicine.medical_specialtyRandomizationAnastomosisPerioperative CarepCO2law.inventionRandomized controlled triallawmedicineHumansProspective StudiesAgedAged 80 and overWound Healingbusiness.industryAnastomosis SurgicalOxygen Inhalation TherapyPerioperativeHydrogen-Ion ConcentrationMiddle AgedColorectal surgerySurgeryClinical trialTreatment OutcomeAnesthesiaFemaleSurgeryColorectal NeoplasmsbusinessBlood Gas Monitoring TranscutaneousPerfusionBritish Journal of Surgery
researchProduct